3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Classical hematology
1
Breast
1
Conditions
Multiple Myeloma
2
Lymphoma
2
Venous Thrombosis
1
Venous Thromboembolism
1
Vascular Diseases
1
Urogenital Neoplasms
1
Thromboembolism
1
Prostatic Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Lymphoproliferative Disorders
1
Lymphatic Diseases
1
Lung Neoplasms
1
Leukemia
1
Intestinal Neoplasms
1
Hemostatic Disorders
1
Digestive System Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Tacrolimus
4
Epoetin Alfa
4
Busulfan
4
fludarabine
3
Darbepoetin alfa
3
Bortezomib
3
fludarabine phosphate
2
dacetuzumab
2
Rituximab
2
Peripheral Blood Stem Cell Transplantation
2
Mycophenolic Acid
2
Lenalidomide
2
Early Intervention, Educational
2
Dexamethasone
2
Antilymphocyte Serum
2
Alemtuzumab
2
venetoclax
1
trametinib
1
ruxolitinib
1
plerixafor
1
isatuximab
1
ficlatuzumab
1
ferrous sulfate
1
ferric gluconate
1
ethanolamine oleate
1
dabrafenib
1
Vorinostat
1
Trimethoprim, Sulfamethoxazole Drug Combination
1
Trimethoprim
1
Tinzaparin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoproliferative Disorders
×
Tinzaparin
×
Plasma cell
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled